Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer

NCT00392769 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Endometrial Cancer

Interventions

DRUG: Cetuximab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]